Glycovax Pharma

Biotechnology ResearchQuebec, Canada11-50 Employees

Glycovax Pharma is a Montreal‑based biotechnology research company focused on developing carbohydrate‑based vaccines to meet pressing health needs. Its platform rethinks capsular polysaccharide conjugate vaccines by using fully synthetic carbohydrate antigens paired with a carrier protein and an immunostimulatory adjuvant, aiming to achieve vaccines with optimized reactivity and efficacy. By prioritizing scientific collaboration and leveraging advanced technology, the company seeks to support vaccine developers and protect communities worldwide.

In April 2026, Glycovax announced an exclusive global license with Université Laval to develop and commercialize a family of compounds targeting galectin-3, a cellular protein linked to several fibrotic diseases and related pathologies. Earlier in 2025, the company disclosed a collaboration with the National Research Council of Canada and the Université de Montréal to develop a glycoconjugate vaccine against Pseudomonas aeruginosa infections.

Sign up for free to view info

Email Format Employee directory